DR. REDDYS LAB | MEDICO REMEDIES | DR. REDDYS LAB/ MEDICO REMEDIES |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 19.5 | 57.2 | 34.0% | View Chart |
P/BV | x | 4.4 | 9.1 | 48.2% | View Chart |
Dividend Yield | % | 0.7 | 0.0 | - |
DR. REDDYS LAB MEDICO REMEDIES |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
DR. REDDYS LAB Mar-23 |
MEDICO REMEDIES Mar-23 |
DR. REDDYS LAB/ MEDICO REMEDIES |
5-Yr Chart Click to enlarge
|
||
High | Rs | 4,656 | 87 | 5,354.7% | |
Low | Rs | 3,788 | 16 | 23,672.2% | |
Sales per share (Unadj.) | Rs | 1,481.4 | 16.9 | 8,753.1% | |
Earnings per share (Unadj.) | Rs | 270.7 | 0.9 | 31,012.7% | |
Cash flow per share (Unadj.) | Rs | 345.7 | 1.2 | 28,798.4% | |
Dividends per share (Unadj.) | Rs | 40.00 | 0 | - | |
Avg Dividend yield | % | 0.9 | 0 | - | |
Book value per share (Unadj.) | Rs | 1,389.6 | 5.3 | 26,299.7% | |
Shares outstanding (eoy) | m | 166.53 | 82.98 | 200.7% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 2.8 | 3.0 | 93.7% | |
Avg P/E ratio | x | 15.6 | 59.0 | 26.4% | |
P/CF ratio (eoy) | x | 12.2 | 42.9 | 28.5% | |
Price / Book Value ratio | x | 3.0 | 9.7 | 31.2% | |
Dividend payout | % | 14.8 | 0 | - | |
Avg Mkt Cap | Rs m | 703,039 | 4,272 | 16,458.4% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 46,466 | 57 | 81,806.3% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 246,697 | 1,404 | 17,566.4% | |
Other income | Rs m | 10,555 | 41 | 25,838.4% | |
Total revenues | Rs m | 257,252 | 1,445 | 17,800.1% | |
Gross profit | Rs m | 63,860 | 95 | 67,355.8% | |
Depreciation | Rs m | 12,502 | 27 | 45,946.3% | |
Interest | Rs m | 1,428 | 7 | 19,116.5% | |
Profit before tax | Rs m | 60,485 | 101 | 59,892.1% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 15,412 | 29 | 53,944.7% | |
Profit after tax | Rs m | 45,073 | 72 | 62,238.3% | |
Gross profit margin | % | 25.9 | 6.8 | 383.4% | |
Effective tax rate | % | 25.5 | 28.3 | 90.1% | |
Net profit margin | % | 18.3 | 5.2 | 354.3% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 203,161 | 662 | 30,702.9% | |
Current liabilities | Rs m | 85,721 | 432 | 19,864.0% | |
Net working cap to sales | % | 47.6 | 16.4 | 290.5% | |
Current ratio | x | 2.4 | 1.5 | 154.6% | |
Inventory Days | Days | 79 | 3 | 3,020.5% | |
Debtors Days | Days | 107 | 938 | 11.4% | |
Net fixed assets | Rs m | 112,638 | 229 | 49,167.6% | |
Share capital | Rs m | 833 | 166 | 501.9% | |
"Free" reserves | Rs m | 230,571 | 272 | 84,625.6% | |
Net worth | Rs m | 231,404 | 438 | 52,780.1% | |
Long term debt | Rs m | 1,278 | 2 | 51,740.9% | |
Total assets | Rs m | 315,799 | 891 | 35,451.6% | |
Interest coverage | x | 43.4 | 14.5 | 298.6% | |
Debt to equity ratio | x | 0 | 0 | 98.0% | |
Sales to assets ratio | x | 0.8 | 1.6 | 49.6% | |
Return on assets | % | 14.7 | 9.0 | 164.2% | |
Return on equity | % | 19.5 | 16.5 | 117.9% | |
Return on capital | % | 26.6 | 24.6 | 108.2% | |
Exports to sales | % | 52.2 | 88.0 | 59.3% | |
Imports to sales | % | 16.8 | 8.6 | 195.1% | |
Exports (fob) | Rs m | 128,803 | 1,236 | 10,417.7% | |
Imports (cif) | Rs m | 41,484 | 121 | 34,278.6% | |
Fx inflow | Rs m | 128,803 | 1,236 | 10,417.7% | |
Fx outflow | Rs m | 41,484 | 124 | 33,349.9% | |
Net fx | Rs m | 87,319 | 1,112 | 7,852.4% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 58,875 | 82 | 72,088.9% | |
From Investments | Rs m | -41,373 | -66 | 62,648.4% | |
From Financial Activity | Rs m | -26,861 | -18 | 147,831.6% | |
Net Cashflow | Rs m | -9,073 | -3 | 357,204.7% |
Indian Promoters | % | 26.7 | 73.3 | 36.3% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 47.3 | 1.0 | 4,589.3% | |
FIIs | % | 28.6 | 0.3 | 9,869.0% | |
ADR/GDR | % | 15.3 | 0.0 | - | |
Free float | % | 58.0 | 26.7 | 217.6% | |
Shareholders | 257,794 | 10,685 | 2,412.7% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare DR. REDDYS LAB With: DIVIS LABORATORIES SUN PHARMA CIPLA ZYDUS LIFESCIENCES MANKIND PHARMA
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | Dr. Reddys | MEDICO REMEDIES | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | 0.46% | 0.90% | 0.10% |
1-Month | -4.10% | -38.23% | 2.44% |
1-Year | 23.75% | -36.28% | 52.90% |
3-Year CAGR | 6.95% | 106.45% | 14.89% |
5-Year CAGR | 16.77% | 61.27% | 19.33% |
* Compound Annual Growth Rate
Here are more details on the Dr. Reddys share price and the MEDICO REMEDIES share price.
Moving on to shareholding structures...
The promoters of Dr. Reddys hold a 26.7% stake in the company. In case of MEDICO REMEDIES the stake stands at 73.3%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of Dr. Reddys and the shareholding pattern of MEDICO REMEDIES .
Finally, a word on dividends...
In the most recent financial year, Dr. Reddys paid a dividend of Rs 40.0 per share. This amounted to a Dividend Payout ratio of 14.8%.
MEDICO REMEDIES paid Rs 0.0, and its dividend payout ratio stood at 0.0%.
You may visit here to review the dividend history of Dr. Reddys, and the dividend history of MEDICO REMEDIES .
For a sector overview, read our pharmaceuticals sector report.
Asian share markets are mixed today after US shares extended their losing streak to the longest since January 2024.